AstraZeneca continues yard-sale strategy with $538M Seroquel rights deal

AstraZeneca is back at it again with asset sales. The company, which has taken some flak for a series of deals to offload asset rights, inked an agreement with Luye Pharma for legacy antipsychotic Seroquel and an extended-release version.

• Source: fiercepharma
• 675
• May 10, 2018